Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Net Income (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Net Income for 11 consecutive years, with $8.6 million as the latest value for Q4 2025.

  • Quarterly Net Income rose 69.32% to $8.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.0 million through Dec 2025, down 8.71% year-over-year, with the annual reading at -$12.2 million for FY2025, 13.35% down from the prior year.
  • Net Income for Q4 2025 was $8.6 million at Marker Therapeutics, up from -$2.0 million in the prior quarter.
  • The five-year high for Net Income was $8.7 million in Q4 2023, with the low at -$10.9 million in Q2 2021.
  • Average Net Income over 5 years is -$2.7 million, with a median of -$2.4 million recorded in 2024.
  • Peak annual rise in Net Income hit 1173.9% in 2023, while the deepest fall reached 637.25% in 2023.
  • Over 5 years, Net Income stood at -$9.8 million in 2021, then soared by 91.67% to -$813062.0 in 2022, then skyrocketed by 1173.9% to $8.7 million in 2023, then tumbled by 41.73% to $5.1 million in 2024, then skyrocketed by 69.32% to $8.6 million in 2025.
  • According to Business Quant data, Net Income over the past three periods came in at $8.6 million, -$2.0 million, and -$4.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.